Form 4: Clene Inc. CEO Granted Stock Options

Clene Inc.'s CEO, Robert Dee Etherington, was granted stock options for a total of 3,150,000 shares on June 7, 2024.

Summary

• Robert Dee Etherington, CEO of Clene Inc., was granted stock options on June 7, 2024.
• The options are for 900,000 shares and 2,250,000 shares of Clene Inc. Common Stock under the Clene Inc. Amended 2020 Stock Plan.
• The exercise price for both options is $0.37 per share.
• The first option for 900,000 shares vests with respect to the first 25% of such shares on June 7, 2025 and then in 36 equal installments of Common Stock on the 7th day of each calendar month, beginning July 7, 2025, until such shares are fully vested.
• The second option for 2,250,000 shares vests in three tranches based on specific milestones: NDA acceptance by the FDA (33.3%), NDA approval by the FDA (33.3%), and achieving $100,000,000 in revenues from approved drug sales (33.4%).
• The expiration date for both options is June 6, 2034.

Sentiment

Score: 7

Explanation: The document indicates standard executive compensation practices with incentives tied to company performance, which is generally viewed positively.

Positives

• The vesting of a portion of the options is tied to achieving significant milestones, such as FDA approval and revenue targets, which aligns management's interests with the company's success.

Risks

• The vesting of a significant portion of the options depends on the company achieving regulatory approvals and revenue targets, which are subject to uncertainty.

Future Outlook

The vesting of a significant portion of the options is contingent upon Clene Inc. achieving key regulatory and financial milestones, indicating the company's focus on obtaining FDA approvals and generating substantial revenue from its products.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives, particularly in companies focused on drug development and regulatory approvals. The vesting conditions tied to FDA milestones and revenue targets are designed to align management's interests with the company's long-term success.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like BioNTech and Moderna also use stock options with vesting schedules tied to clinical trial milestones and regulatory approvals.
• The size of the grant (3,150,000 shares) should be compared to similar companies of Clene Inc.'s market capitalization and stage of development to assess its relative value.

Stakeholder Impact

• Shareholders: The stock options could potentially dilute existing shareholders if exercised, but the vesting conditions are designed to align management's interests with increasing shareholder value.
• Employees: The stock options granted to the CEO could motivate employees by aligning leadership's incentives with the company's success.

Key Dates